Your Cart

Renounceable Rights Issue Letter to Shareholders

Renounceable Rights Issue Letter to Shareholders

Imagion Biosystems has announced a letter to shareholders regarding the 28 October 2019 announcement of a renounceable pro-rata offer.
Read the letter to shareholders.

Related Articles

1H2023 Half-Year Results

1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan

Read More

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.